Ven­tyx ax­es de­vel­op­ment of TYK2 in­hibitor fol­low­ing Phase 2 fail­ure

Ven­tyx Bio­sciences is shelv­ing a drug af­ter a mid-stage miss and fail­ure.

The com­pa­ny was in­ves­ti­gat­ing VTX958, an al­losteric TYK2 in­hibitor, in pa­tients with mod­er­ate­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER